Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
Cardiovascular disease (CVD) is the leading cause of premature death on aglobal scale and is projected to remain so in the near future. CVD encompassescoronary artery disease, hypertension, heart failure and cardiomyopathy. Themechanical failure of the heart due to CVD affects the conduction system ofthe heart. Depending on the level of malfunction, the manifestation of outcomevaries from angina pectoris to ventricular arrhythmia.
Advertisement
Demographics such as the increasing baby-boomer population, sedentarylifestyle, and increased disorders such as obesity, diabetes, smoking andothers often result in cardiovascular ailments like for example arrhythmia,congestive heart failure, cardiomyopathy, and atherosclerosis. Risingawareness for such ailments and potentially increasing diagnostics help toattract interest of the target population.
At the same time, the Western European industry for Cardiac RhythmManagement is facing a high degree of consolidation, which has led tostrenuous competition. The major participants in the market try to acquire thesmaller ones, making it difficult for the niche participants to survive. Brandloyalty of devices forms an additional factor that creates a hostile platformfor new players entering the market, because customers are often loyal totheir chosen brand which reflects in their repurchase behaviour.
Collaborative partnerships, together with technological innovations andscalability will therefore determine the future of this market.
Highlights of the Frost & Sullivan briefing include analyses of R&Dinvestment, challenges and drivers of the Cardiac Rhythm Management Market,and reasons for stakeholders to invest in the medical device industry. Thebriefing will benefit medical device manufacturers, distributors andcardiologists.
"Despite the global economic meltdown, the Cardiac Rhythm Managementindustry has survived the tough weather owing to its pocket being deep enoughto wield over," concludes SreeVidhya Praveenkumar, Research Associate fromFrost & Sullivan.
Frost & Sullivan will hold this conference call at 4 p.m. GMT onWednesday, 25 February, 2009, which will provide industry participants anoutlook of the European Cardiac Rhythm Management Market. To participate,please email Katja Feick at [email protected] with the followinginformation: your full name, company name, title, telephone number, e-mailaddress, city, state, and country. Upon receipt of the above information, aregistration link will be emailed to you.
Frost & Sullivan has expanded its flagship Global Congress on CorporateGrowth - GIL Global - into several major cities around the world includingLondon. For the first time ever in Europe, Frost & Sullivan will be hostingthe Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20May, at the Sofitel St James in London. GIL Global is the industry's onlyevent designed to support senior executives in their efforts to achievesustainable, top-line growth. To register, obtain a programme agenda, exploresponsorship opportunities, or attend as a member of the media for GIL 2009:Europe, please contact Katja Feick, Corporate Communications Europe, [email protected]. One-on-One interviews with Frost & Sullivan seniorgrowth consultants are also being scheduled. For more information you canalso visit www.frost.com/giluk
Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting andGrowth Team Membership empower clients to create a growth-focused culture thatgenerates, evaluates and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses and the investment community from more than 30offices on six continents. For more information about Frost & Sullivan'sGrowth Partnerships, visit http://www.frost.com.Contact: Katja Feick Corporate Communications - Europe P: 0049 (0) 69 77 0 33 43 F: 0049 (0) 69 23 45 66 E: [email protected] www.frost.com
SOURCE Frost & Sullivan
